Beijing Continent Pharmaceuticals Co., Ltd.(also known as Gyre Pharmaceuticals Co., Ltd.) was founded in 2002, which is a innovate drug development enterprise committed to organ fibrosis diseases, and integrated R&D, production and commercialization. Gyre Pharmaceuticals is the holding subsidiary of the NASDAQ-listed company Gyre Therapeutics, Inc. (NASDAQ: GYRE).
As a pioneer in the field of anti-organ fibrosis, company's flagship product Class 1.1 new drug ETUARY® (Pirfenidone Capsule) is one of the only two types approved drugs for IPF treatment worldwide. As the first innovate drug approved to be used for IPF in China, it filled the gap in the IPF treatment field after its successful launch in 2014. F351 (Hydronidone) the company's key production for next stage, was granted a Breakthrough Therapy designation as the liver fibrosis treatment drug by the CDE. It is expected to be the first approved drug for the treatment of liver fibrosis associated with CHB.
Company Details
- Founded
- -
- Address
- Beijng, Cn
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- https://www.bjcontinent.com/en/
- Keywords
- IT Consulting.
- HQ
- Beijng
Gyre Pharmaceuticals Questions
Gyre Pharmaceuticals's website is https://www.bjcontinent.com/en/
Gyre Pharmaceuticals's LinkedIn profile is https://cn.linkedin.com/company/gyrepharmaceuticals
Gyre Pharmaceuticals's industry is
Pharmaceutical Manufacturing
Gyre Pharmaceuticals's top competitors are
Align Technology,
Gyre Therapeutics,
Rabung Hr Consultancy Pvt. Ltd.,
Sanbio,
Gaba Northern California - German American Business Association,
Gyre Bio,
Catalyst Biosciences,
Eklogi Consulting Llp,
Gni Group Ltd.,
Hong Kong Talent Engage.
Gyre Pharmaceuticals's categories are Pharmaceutical Manufacturing
Gyre Pharmaceuticals's founding year is 2002
